Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: Short-course rapamycin treatment enables engraftment of immunogenic gene-engineered bone marrow under low-dose irradiation to permit long-term immunological tolerance

Fig. 5

Rapamycin inhibits T-cell effector differentiation during tolerance induction. a–g Naive OT-I cells were transferred to 11c.OVA mice and rapamycin (rapa), cyclosporine (CyA) or PBS was administered 3 hrs before adoptive transfer and daily thereafter. Three days (a–c) or 7 days (d–f) after OT-I transfer, spleens were harvested and OT-I cells enumerated in the spleen (a, d), the proportion of OT-I T cells producing IFN-γ was determined by intracellular cytokine staining (b, e) and the total number of IFN-γ-producing OT-I T cells per spleen calculated (c, f) were determined. g BM (107 cells) from non-Tg and MII.OVA mice was transferred i.v. to B6.SJL mice under low-dose irradiation (300 cGy TBI). Rapamycin (0.6 mg/kg) or PBS was administered i.p. for 16 days commencing at BM transfer. The day after rapamycin cessation an in-vivo CTL assay was performed. Data represent individual mice pooled from two experiments (mean ± SEM). ANOVA with Tukey’s post test. BM bone marrow

Back to article page